CDK 4/6 Inhibitor LEE011 (Ribociclib) in Combination With Adjuvant Endocrine Therapy at Varying Duration for ER-positive Breast Cancer

Study Overview

This research study is studying a drug as a possible treatment for ER-positive Breast Cancer

The drug involved in this study is:

-Ribociclib

Study Description

Phase II Study of CDK 4/6 Inhibitor, LEE011 (Ribociclib), in combination with Adjuvant endocrine therapy at varying Duration for ER-positive Breast Cancer (LEADER)

  • ClinicalTrials.gov Identifier: NCT03285412
  • Protocol Number: 17-232
  • Principal Investigator: Jaymin Patel

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000